[go: up one dir, main page]

PE20140189A1 - Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c - Google Patents

Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c

Info

Publication number
PE20140189A1
PE20140189A1 PE2013001102A PE2013001102A PE20140189A1 PE 20140189 A1 PE20140189 A1 PE 20140189A1 PE 2013001102 A PE2013001102 A PE 2013001102A PE 2013001102 A PE2013001102 A PE 2013001102A PE 20140189 A1 PE20140189 A1 PE 20140189A1
Authority
PE
Peru
Prior art keywords
hepatitis
virus
inhibitors
compounds containing
containing quinoxaline
Prior art date
Application number
PE2013001102A
Other languages
English (en)
Inventor
Yonghua Gai
Yat Sun Or
Zhe Wang
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Publication of PE20140189A1 publication Critical patent/PE20140189A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS QUE CONTIENEN QUINOXALINA COMO INHIBIDORES DEL VIRUS DE LA HEPATITIS C, DE FORMULA I: DONDE A ES S(O)2 ENTRE OTROS; L201 ES C1-C8 ALQUILENO, C2-C8 ALQUENILENO, ENTRE OTROS; M ES O, S, SO, SO2 ENTRE OTROS, L101 ES C1-C8 ALQUILENO, C2-C8 ALQUENILENO ENTRE OTROS; Z101 ES FENILO, FENILO SUSTITUIDO CON 1, 2 O 3, ENTRE OTROS; W101 ES O, S, C(O9); X Y Y FORMAN UN ANILLO FENILO; R ES C1-C8 ALQUILO; R' ES C1-C8 ALQUILO, C2-C8 ALQUENILO, ENTRE OTROS; G ES OH, NHS(O)2 ENTRE OTROS; m ES 1; m' ES 1; s es 1-4. ES COMPUESTO PREFERIDO DE FORMULA (II) TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS Y SON UTILES COMO AGENTES ANTIVIRALES.
PE2013001102A 2007-11-14 2008-11-14 Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c PE20140189A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98795807P 2007-11-14 2007-11-14
US2545808P 2008-02-01 2008-02-01

Publications (1)

Publication Number Publication Date
PE20140189A1 true PE20140189A1 (es) 2014-03-12

Family

ID=40639146

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2008001930A PE20091212A1 (es) 2007-11-14 2008-11-14 Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c
PE2013001102A PE20140189A1 (es) 2007-11-14 2008-11-14 Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2008001930A PE20091212A1 (es) 2007-11-14 2008-11-14 Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c

Country Status (26)

Country Link
US (2) US8324155B2 (es)
EP (1) EP2219453B1 (es)
JP (1) JP5479354B2 (es)
KR (1) KR20100098527A (es)
CN (1) CN101909446A (es)
AR (1) AR069464A1 (es)
AU (1) AU2008322537A1 (es)
BR (1) BRPI0820085A2 (es)
CA (1) CA2705807A1 (es)
CL (1) CL2008003384A1 (es)
CO (1) CO6280441A2 (es)
CR (1) CR11499A (es)
DO (1) DOP2010000143A (es)
EC (1) ECSP10010254A (es)
ES (1) ES2476257T3 (es)
HK (1) HK1146693A1 (es)
IL (1) IL205611A0 (es)
MX (1) MX2010005262A (es)
MY (1) MY155851A (es)
PE (2) PE20091212A1 (es)
RU (1) RU2493160C2 (es)
TW (1) TWI431011B (es)
UA (1) UA102677C2 (es)
UY (1) UY31470A1 (es)
WO (1) WO2009064975A1 (es)
ZA (1) ZA201003363B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006119061A2 (en) 2005-05-02 2006-11-09 Merck & Co., Inc. Hcv ns3 protease inhibitors
US7470664B2 (en) 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
CA2615896C (en) 2005-08-01 2012-11-13 Merck & Co., Inc. Macrocyclic peptides as hcv ns3 protease inhibitors
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
US8377873B2 (en) 2006-10-24 2013-02-19 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8138164B2 (en) 2006-10-24 2012-03-20 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
JP5345941B2 (ja) 2006-10-24 2013-11-20 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖｎｓ３プロテアーゼ阻害剤
MY164469A (en) 2006-10-27 2017-12-15 Msd Italia Srl Hcv ns3 protease inhibitors
JP5352464B2 (ja) 2006-10-27 2013-11-27 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖｎｓ３プロテアーゼ阻害剤
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008075103A1 (en) 2006-12-20 2008-06-26 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Antiviral indoles
CN101801982A (zh) 2007-07-17 2010-08-11 P.安杰莱蒂分子生物学研究所 用于治疗丙型肝炎感染的大环吲哚衍生物
CN101754974B (zh) 2007-07-19 2016-02-03 Msd意大利有限公司 作为抗病毒剂的大环化合物
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
WO2009070689A1 (en) * 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease
US8273709B2 (en) 2007-12-14 2012-09-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic HCV serine protease inhibitors
US8222203B2 (en) * 2007-12-14 2012-07-17 Enanta Pharmaceuticals, Inc. Macrocyclic oximyl hepatitis C serine protease inhibitors
US8283309B2 (en) 2007-12-20 2012-10-09 Enanta Pharmaceuticals, Inc. Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors
CN102036966A (zh) * 2008-01-24 2011-04-27 益安药业 作为hcv丝氨酸蛋白酶抑制剂的二氟化三肽
WO2009134624A1 (en) 2008-04-28 2009-11-05 Merck & Co., Inc. Hcv ns3 protease inhibitors
US8211891B2 (en) * 2008-04-30 2012-07-03 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors
EP2310095B1 (en) 2008-07-22 2012-08-29 Merck Sharp & Dohme Corp. Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
JP5639155B2 (ja) * 2009-05-13 2014-12-10 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルスインヒビターとしての大環状化合物
WO2011014487A1 (en) 2009-07-30 2011-02-03 Merck Sharp & Dohme Corp. Hepatitis c virus ns3 protease inhibitors
WO2011049908A2 (en) 2009-10-19 2011-04-28 Enanta Pharmaceuticals, Inc. Bismacrokyclic compounds as hepatitis c virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
AU2011207492A1 (en) 2010-01-25 2012-08-16 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CA2788155C (en) 2010-01-27 2018-04-24 AB Pharma Ltd. Polyheterocyclic compounds highly potent as hcv inhibitors
US9127021B2 (en) 2010-04-09 2015-09-08 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8778938B2 (en) 2010-06-04 2014-07-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
NZ608720A (en) * 2010-09-21 2015-03-27 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012171332A1 (zh) 2011-06-16 2012-12-20 爱博新药研发(上海)有限公司 抑制丙型肝炎病毒的大环状杂环化合物及其制备和应用
ES2656087T3 (es) 2012-06-08 2018-02-23 Gilead Sciences, Inc. Inhibidores macrocíclicos de virus Flaviviridae
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
CN104703991B (zh) 2012-06-08 2018-03-23 吉利德科学公司 黄病毒科病毒的大环抑制剂
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
WO2014062196A1 (en) 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
EP2970335B1 (en) 2013-03-15 2019-05-08 Gilead Sciences, Inc. Macrocyclic and bicyclic inhibitors of hepatitis c virus
CN116813596A (zh) * 2013-12-23 2023-09-29 吉利德科学公司 大环hcv ns3抑制三肽的合成
WO2015100144A1 (en) * 2013-12-23 2015-07-02 Gilead Sciences, Inc. Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
CN107074876B (zh) * 2016-04-08 2019-12-20 上海长森药业有限公司 一类抑制丙肝病毒的大环状杂环化合物及其制备和用途
CN107266529A (zh) * 2016-04-08 2017-10-20 上海长森药业有限公司 一类抑制丙肝病毒的大环状杂环化合物及其制备和用途
RU2650610C1 (ru) * 2017-02-28 2018-04-16 Васильевич Иващенко Александр Противовирусная композиция и способ ее применения
CN107987083A (zh) * 2017-11-24 2018-05-04 江苏亚盛医药开发有限公司 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60137207D1 (de) 2000-04-05 2009-02-12 Schering Corp Makrozyklische inhibitoren der ns3-serinprotease des hepatitis c-virus mit stickstoffhaltigen zyklischen p2-gruppen
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7176208B2 (en) * 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
PA8603801A1 (es) * 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
WO2006119061A2 (en) 2005-05-02 2006-11-09 Merck & Co., Inc. Hcv ns3 protease inhibitors
US7470664B2 (en) 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
CA2615666C (en) * 2005-07-25 2014-08-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
CA2615896C (en) * 2005-08-01 2012-11-13 Merck & Co., Inc. Macrocyclic peptides as hcv ns3 protease inhibitors
GB0609492D0 (en) * 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) * 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
UY30437A1 (es) * 2006-06-26 2008-01-31 Enanta Pharm Inc Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
US7635683B2 (en) * 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
US7582605B2 (en) * 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors
MY164469A (en) * 2006-10-27 2017-12-15 Msd Italia Srl Hcv ns3 protease inhibitors
US8377872B2 (en) * 2007-04-26 2013-02-19 Enanta Pharmaceuticals, Inc. Cyclic P3 tripeptide hepatitis C serine protease inhibitors
WO2008134397A1 (en) * 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Aza-tripeptide hepatitis c serine protease inhibitors
US20080267917A1 (en) * 2007-04-26 2008-10-30 Deqiang Niu N-functionalized amides as hepatitis c serine protease inhibitors
CN101754974B (zh) 2007-07-19 2016-02-03 Msd意大利有限公司 作为抗病毒剂的大环化合物
US8383583B2 (en) * 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
WO2009064955A1 (en) * 2007-11-14 2009-05-22 Enanta Pharmaceuticals, Inc. Macrocyclic tetrazolyl hepatitis c serine protease inhibitors
CN101932242A (zh) * 2007-12-05 2010-12-29 益安药业 喹喔啉基衍生物
CN101977621A (zh) * 2007-12-05 2011-02-16 益安药业 氟化三肽hcv丝氨酸蛋白酶抑制剂
US8222203B2 (en) * 2007-12-14 2012-07-17 Enanta Pharmaceuticals, Inc. Macrocyclic oximyl hepatitis C serine protease inhibitors
US8273709B2 (en) * 2007-12-14 2012-09-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic HCV serine protease inhibitors
US8283309B2 (en) * 2007-12-20 2012-10-09 Enanta Pharmaceuticals, Inc. Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors

Also Published As

Publication number Publication date
RU2493160C2 (ru) 2013-09-20
US8324155B2 (en) 2012-12-04
UA102677C2 (uk) 2013-08-12
US20130144036A1 (en) 2013-06-06
CO6280441A2 (es) 2011-05-20
IL205611A0 (en) 2010-11-30
WO2009064975A1 (en) 2009-05-22
AU2008322537A1 (en) 2009-05-22
CN101909446A (zh) 2010-12-08
MX2010005262A (es) 2010-08-10
US20100003214A1 (en) 2010-01-07
ZA201003363B (en) 2011-04-28
US8951998B2 (en) 2015-02-10
CL2008003384A1 (es) 2009-12-11
TW200938550A (en) 2009-09-16
AR069464A1 (es) 2010-01-27
ES2476257T3 (es) 2014-07-14
CA2705807A1 (en) 2009-05-22
HK1146693A1 (en) 2011-07-08
EP2219453B1 (en) 2014-04-09
KR20100098527A (ko) 2010-09-07
DOP2010000143A (es) 2010-07-31
CR11499A (es) 2010-10-25
RU2010123928A (ru) 2011-12-20
EP2219453A1 (en) 2010-08-25
ECSP10010254A (es) 2010-07-30
EP2219453A4 (en) 2011-01-19
JP5479354B2 (ja) 2014-04-23
PE20091212A1 (es) 2009-09-13
TWI431011B (zh) 2014-03-21
MY155851A (en) 2015-12-15
JP2011505339A (ja) 2011-02-24
UY31470A1 (es) 2009-07-17
BRPI0820085A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
PE20140189A1 (es) Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c
MA55131B1 (fr) Nouveaux composés hétérocycliques
MA37942B1 (fr) Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b
AR055635A1 (es) Uso de sulfonanilidas como herbicidas
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
MA34389B1 (fr) Nouvelles aminopyrazoloquinazolines
MA34836B1 (fr) Composes heterocycliques azotes 6;6- condenses substitues et leurs utilisations
ES2517873T3 (es) Composiciones orgánicas fluorescentes
UY29388A1 (es) Derivados del (1,5-difenil-h-pirazol-3-il)oxadiazol, su preparación y su aplicacion en terapéutica.
NO20084515L (no) Flottasjonsreagens for mineraler inneholdende silikater
MA37756A1 (fr) Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane
CR9602A (es) Nuevos derivados de 2,4-dianilinpirimidinas, su preparacion, como medicamentos, composiciones farmaceuticas y particularmente como inhibidores de ikk
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
PE20151951A1 (es) Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
CA2737562A1 (en) Amide gellant compounds with aromatic end groups
BR112013025456A2 (pt) composição curável útil para uso como material de circulação perdido em perfuração de poços
MX2018016410A (es) Composicion para eliminar un compuesto que contiene azufre.
AR067691A1 (es) Derivados heterociclicos de sulfonimidoil, composiciones plaguicidas que los contienen y usos de los mismos para el control de plagas.
MA33652B1 (fr) Agent stabilisant aminé stériquement encombré
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
MA38865A1 (fr) Formulation comprenant un agent hypolipidémiant
CO6450648A2 (es) Compuesto ciclico que tiene grupo fenilo sustituido
PE20150877A1 (es) Composicion herbicida que tiene actividad herbicida mejorada
MX2016005993A (es) Anfifilos biscationicos y triscationicos como agentes antimicrobianos.

Legal Events

Date Code Title Description
FC Refusal